← Back to Search
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
S. Kleffel, C. Posch, S. Barthel, H. Mueller, C. Schlapbach, E. Guenova, C. P. Elco, Nayoung Lee, Vikram R. Juneja, Q. Zhan, C. Lian, R. Thomi, W. Hoetzenecker, A. Cozzio, R. Dummer, M. Mihm, K. Flaherty, M. Frank, G. F. Murphy, A. Sharpe, T. Kupper, T. Schatton
Published 2015 · Biology, Medicine
Download PDFAnalyze on Scholarcy
Therapeutic antibodies targeting programmed cell death 1 (PD-1) activate tumor-specific immunity and have shown remarkable efficacy in the treatment of melanoma. Yet, little is known about tumor cell-intrinsic PD-1 pathway effects. Here, we show that murine and human melanomas contain PD-1-expressing cancer subpopulations and demonstrate that melanoma cell-intrinsic PD-1 promotes tumorigenesis, even in mice lacking adaptive immunity. PD-1 inhibition on melanoma cells by RNAi, blocking antibodies, or mutagenesis of melanoma-PD-1 signaling motifs suppresses tumor growth in immunocompetent, immunocompromised, and PD-1-deficient tumor graft recipient mice. Conversely, melanoma-specific PD-1 overexpression enhances tumorigenicity, as does engagement of melanoma-PD-1 by its ligand, PD-L1, whereas melanoma-PD-L1 inhibition or knockout of host-PD-L1 attenuate growth of PD-1-positive melanomas. Mechanistically, the melanoma-PD-1 receptor modulates downstream effectors of mTOR signaling. Our results identify melanoma cell-intrinsic functions of the PD-1:PD-L1 axis in tumor growth and suggest that blocking melanoma-PD-1 might contribute to the striking clinical efficacy of anti-PD-1 therapy.
This paper references
Combined targeting ofMEK andPI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo
C. Posch (2013)
The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
X. Jiang (2012)
From genes to drugs: targeted strategies for melanoma
K. Flaherty (2012)
Protein-tyrosine phosphatases and cancer
Arne Östman (2006)
Immune Checkpoint Blockade in Cancer Therapy
J. Allison (2008)
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
O. Hamid (2013)
Genetic basis 1256 Cell 162 , 1242 – 1256 , September 10 , 2015 a 2015 Elsevier Inc . for clinical response to CTLA - 4 blockade in melanoma
A. Snyder (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
P. Tumeh (2014)
Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth.
G. Civenni (2011)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
H. Dong (2002)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
R. Herbst (2014)
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
Seng-Ryong Woo (2012)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.
Suzanne L. Topalian (2012)
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
N. Rizvi (2015)
Modulation of T-cell activation by malignant melanoma initiating cells.
T. Schatton (2010)
Faculty Opinions recommendation of Nivolumab plus ipilimumab in advanced melanoma.
R. Arenas (2013)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
J. Weber (2015)
AC Tose (1993)
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo
C. Posch (2013)
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll (2012)
Microenvironment and Immunology PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-g Inducible Chemokines
W. Peng (2012)
TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma
R. Corcoran (2013)
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
A. Snyder (2014)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment: a randomised, controlled, openlabel , phase 3 trial
J S Weber (2015)
Nivolumab plus ipilimumab in advanced melanoma.
J. Wolchok (2013)
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients
J. Fourcade (2010)
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines.
W. Peng (2012)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi (2010)
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
M. Yadav (2014)
Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop
N. Aceto (2012)
Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens
M. M. Gubin (2014)
CTLA-4 blockade in melanoma
S. L. Topalian (2012)
Identification of cells initiating human melanomas
B. Thiers (2009)
PD‐1 signaling in primary T cells
J. Riley (2009)
SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans.
K. Liu (2011)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco (2009)
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)
This paper is referenced by
Systemic immune‐checkpoint blockade with anti‐PD1 antibodies does not alter cerebral amyloid‐β burden in several amyloid transgenic mouse models
Martine Latta-Mahieu (2018)
Neue Studienprodukte in der onkologischen Immuntherapie
V. Gruenwald (2016)
Clinical significance of T cell metabolic reprogramming in cancer
Christoph Herbel (2016)
Programmed cell death protein 1 promotes hepatitis B virus transmission through the regulation of ERK1/2-mediated trophoblasts differentiation
Jielian Yang (2019)
Cancer immunoediting and resistance to T cell-based immunotherapy
J. S. O’Donnell (2018)
Immune checkpoints in tumor microenvironment and their relevance to the development of cancer stem cells.
N. Khosravi (2020)
From biomarkers to therapeutic targets: the promise of PD-L1 in thyroid autoimmunity and cancer
Grégoire D’Andréa (2020)
PD-L1 Influences Cell Spreading, Migration and Invasion in Head and Neck Cancer Cells
Jonas Eichberger (2020)
Programmed cell death ligand 1 (PD‐L1) expression is not a predominant feature in Ewing sarcomas
Christian Spurny (2018)
The tumor microenvironment: Thousand obstacles for effector T cells.
C. Massa (2017)
Trial watch: Immune checkpoint blockers for cancer therapy
Claire Vanpouille-Box (2017)
Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma
Zhitao Dong (2019)
p50 suppresses cytotoxic T lymphocyte effector function to regulate tumor immune escape and response to immunotherapy
Chunwan Lu (2020)
The pd-l1/pd-1 axis blocks neutrophil cytotoxicity in cancer
Maya Gershkovitz (2020)
Efficacy of Juzentaihoto for Tumor Immunotherapy in B16 Melanoma Metastasis Model
Shintaro Ishikawa (2017)
PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load
Yajuan Zhou (2017)
Sevoflurane depletes macrophages from the melanoma microenvironment
Isabella Sztwiertnia (2020)
Proteomic identification of a marker signature for MAPKi resistance in melanoma
V. Paulitschke (2019)
Significant benefit of Nivolumab treating PD-L1 positive metastatic pulmonary carcinosarcoma: a case report and literature review.
Zhe Zhang (2017)
PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: the correlation with anemia and outcomes.
Y. Zhou (2017)
The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment
Katie M Hudson (2020)
Skin Cancers in Organ Transplant Recipients
A. Mittal (2017)
Title HTLV-1 bZIP Factor Impairs Anti-viral Immunity by Inducing Co-inhibitory Molecule, T Cell Immunoglobulin and ITIM
K. Yasuma (2019)
Cell Stemness, Epithelial-to-Mesenchymal Transition, and Immunoevasion: Intertwined Aspects in Cancer Metastasis.
S. Romano (2019)
Local IL-15-immunotherapy to treat melanoma
M. Hanes (2017)
2D kinetic study of of PD-1 interaction and its inhibition of T-cell antigen recognition
Kaitao Li (2016)
Brain metastases : immune characterisation and the impact over prognosis
Catarina Pinheiro Barracha Pinto de Abreu (2019)
PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma
D. Kollmann (2018)
Revving the CAR - Combination strategies to enhance CAR T cell effectiveness.
Rajat Bansal (2020)
PD-L1 promotes head and neck squamous cell carcinoma cell growth through mTOR signaling
A. Zheng (2019)
Mild Innate Immune Activation Overrides Efficient Nanoparticle-Mediated RNA Delivery.
Melissa P. Lokugamage (2019)
Translational Potential of Therapeutics Targeting Regulatory Myeloid Cells in Tuberculosis
N. Du Plessis (2018)See more